Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on AstraZeneca (AZN) to 11,000 GBp from 10,500 GBp and keeps a Sell rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- White House releases details on Trump ‘Great Healthcare Plan’
- Former Emergent BioSolutions CEO sued by NY AG for insider trading
- AstraZeneca’s Imfinzi Post‑Marketing Study in Japan: What the Completed Safety Tracking Means for Investors